Multi-Target-Directed Ligands Targeting Sigma Receptors and the Proteasome—A Holistic Strategy for Cancer Drug Discovery
Molecules · 19.11.2026 · 31 (22) · 4197
DOI: 10.3390/molecules31224197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 19.11.2026. Verfasst von Melania Elettra Vaccari und 8 weiteren Autor:innen. Die Arbeit nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Progetti di Ricerca di Interesse Nazionale 2022.
Abstract (Originalsprache)
Cancer cells employ multiple pro-survival strategies, including evasion of apoptosis and escape from immune surveillance. In particular, cancer cells can modulate intracellular calcium homeostasis and exploit sigma receptor (SR) activity to restore calcium balance. Furthermore, the positive correlation between sigma-1 receptor (S1R) and programmed death-ligand 1 (PD-L1) expression levels suggests that S1R may also contribute to immune evasion. Cancer cells maintain proteostasis through enhanced unfolded protein response (UPR) signaling and activation of the ubiquitin–proteasome system (UPS). The proteasome removes misfolded and ubiquitinated proteins, thereby preventing the accumulation of proteotoxic stress, endoplasmic reticulum (ER) stress, and cell death. Collectively, these adaptive mechanisms enable cancer cells to survive, proliferate, and invade, thereby promoting tumor progression. Although proteasome inhibitors (PIs) have been introduced into clinical practice for the treatment of multiple myeloma (MM), their therapeutic use is limited by several drawbacks, including the development of resistance and limited selectivity. Importantly, SRs play a pivotal role in UPR and UPS signaling; therefore, their modulation may compensate for the limitations associated with PI therapy. Consequently, a holistic strategy that simultaneously targets SRs, UPR signaling, and proteasome function may effectively disrupt key pro-survival pathways of cancer cells and represent a promising paradigm for the development of innovative anticancer therapeutics. In the present perspective, we discuss how such multi-target directed ligands (MTDLs) may offer the advantages of simultaneously hitting multiple key pathways and/or their pathogenic cross-talk with a single chemical entity.
Förderung
- Progetti di Ricerca di Interesse Nazionale 2022
Zitieren
APA
Vaccari, M. E., Salvi, S., Rossino, G., Linciano, P., Rossi, D., Molteni, L., Malacrida, A., Miloso, M., & Collina, S. (2026). Multi-Target-Directed Ligands Targeting Sigma Receptors and the Proteasome—A Holistic Strategy for Cancer Drug Discovery. Molecules, 31(22), 4197. https://doi.org/10.3390/molecules31224197
Vancouver
Vaccari ME, Salvi S, Rossino G, Linciano P, Rossi D, Molteni L, et al. Multi-Target-Directed Ligands Targeting Sigma Receptors and the Proteasome—A Holistic Strategy for Cancer Drug Discovery. Molecules. 2026;31(22):4197. doi:10.3390/molecules31224197
BibTeX
@article{Vaccari2026,
author = {Vaccari, Melania Elettra and Salvi, Sara and Rossino, Giacomo and Linciano, Pasquale and Rossi, Daniela and Molteni, Laura and Malacrida, Alessio and Miloso, Mariarosaria and Collina, Simona},
title = {Multi-Target-Directed Ligands Targeting Sigma Receptors and the Proteasome—A Holistic Strategy for Cancer Drug Discovery},
journal = {Molecules},
year = {2026},
volume = {31},
number = {22},
pages = {4197},
doi = {10.3390/molecules31224197}
}
EUVIMED